Home | Screening data | Screen comparisons | Search for compounds | Structure search

Compound InformationSONAR Target prediction
Name:

COLISTIMETHATE SODIUM

Unique Identifier:SPE01500206
MolClass: Checkout models in ver1.5 and ver1.0
Molecular Formula:
Molecular Weight:1631.98 g/mol
X log p:-11.16  (online calculus)
Lipinksi Failures2
TPSA515.67
Hydrogen Bond Donor Count:0
Hydrogen Bond Acceptors Count:44
Rotatable Bond Count:47
Canonical Smiles:[Na+].[Na+].[Na+].[Na+].[Na+].[O-]S(=O)(=O)CNCCC(NC(=O)CCCCC(C)C)C(=O)
NC(C(C)O)C(=O)NC(CCNCS([O-])(=O)=O)C(=O)NC1CCNC(=O)C(NC(=O)C(CCNCS([O-
])(=O)=O)NC(=O)C(CCNCS([O-])(=O)=O)NC(=O)C(NC(=O)C(NC(=O)C(CCNCS([O-])
(=O)=O)NC1=O)C(C)CC)C(C)CC)C(C)O
Source:Bacillus colistinus
Reference:Brit.J.Pharmacol.Chemother. 23: 552 (1964)
Therapeutics:antibacterial
Generic_name:Colistimethate
Chemical_iupac_name:pentasodium
[3-[[3-(1-hydroxyethyl)-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-6,9,18-
tris[2-(sulfonatomethylamino)ethyl]-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]carba
moyl]-3-[3-hydroxy-2-[2-(6-methyloctanoylamino)-4-(sulfonatomethylamino)butanoyl]ami
no-butanoyl]amino-propyl]aminomethanesulfonate
Drug_type:Approved Drug
Kegg_compound_id:C13553
Drugbank_id:APRD00885
H2o_solubility:Appreciable
Cas_registry_number:8068-28-8
Drug_category:Antibacterial agents
Indication:For the treatment of acute or chronic infections due to sensitive strains of certain
gram-negative bacilli, particularly Pseudomonas aeruginosa.
Pharmacology:Colistimethate is a polymyxin antibiotic agent. Originally, colistimethate sodium
was thought to be less toxic than polymyxin B; however, if the drugs are
administered at comparable doses, their toxicities may be similar. Polymyxins are
cationic polypeptides that disrupt the bacterial cell membrane through a
detergentlike mechanism. With the development of less toxic agents, such as
extended-spectrum penicillins and cephalosporins, parenteral polymyxin use was
largely abandoned, except for the treatment of multidrug-resistant pulmonary
infections in patients with cystic fibrosis. More recently, however, the emergence
of multidrug-resistant gram-negative bacteria, such as Pseudomonas aeruginosa
and Acinetobacter baumannii, and the lack of new antimicrobial agents have
led to the revived use of the polymyxins.
Mechanism_of_action:Colistimethate is a surface active agent which penetrates into and disrupts the
bacterial cell membrane. Colistimethate is polycationic and has both hydrophobic and
lipophilic moieties. It interacts with the bacterial cytoplasmic membrane, changing
its permeability. This effect is bactericidal. There is also evidence that
polymyxins enter the cell and precipitate cytoplasmic components, primarily
ribosomes.
Organisms_affected:Gram-negative bacilli

Found: 205 nonactive | as graph: single | with analogs [1] << Back 21 22 23 24 25 26 27 28 29 30  Next >> [205]
Species: 4932
Condition: DRS2
Replicates: 2
Raw OD Value: r im 0.6830±0.00410122
Normalized OD Score: sc h 0.9894±0.00206481
Z-Score: -0.4602±0.0919376
p-Value: 0.646062
Z-Factor: -8.70533
Fitness Defect: 0.4369
Bioactivity Statement: Nonactive
Experimental Conditions
Library:SPECMTS3
Plate Number and Position:6|A4
Drug Concentration:50.00 nM
OD Absorbance:600 nm
Robot Temperature:22.70 Celcius
Date:2008-01-11 YYYY-MM-DD
Plate CH Control (+):0.041975±0.00078
Plate DMSO Control (-):0.67105±0.01550
Plate Z-Factor:0.9088
png
ps
pdf

DBLink | Rows returned: 5
2835 [[3-[[1-[[1-[[12,15-dibutan-2-yl-3-(1-hydroxyethyl)-2,5,8,11,14,17,20-heptaoxo-6,9,18-tris[2-(sulfonatom
ethylamino)ethyl]-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]carbamoyl]-3-(sulfonatomethylamino)propyl]c
arbamoyl]-2-hydroxy-propyl]carbamoyl]-3-(6-methylheptanoylamino)propyl]amino]methanesulfonate
2836 [[3-[[1-[[1-[[12,15-dibutan-2-yl-3-(1-hydroxyethyl)-2,5,8,11,14,17,20-heptaoxo-6,9,18-tris[2-(sulfomethy
lamino)ethyl]-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]carbamoyl]-3-(sulfomethylamino)propyl]carbamoyl
]-2-hydroxy-propyl]carbamoyl]-3-(6-methylheptanoylamino)propyl]amino]methanesulfonic acid
216258 pentasodium
[[3-[[2-hydroxy-1-[[1-[[3-(1-hydroxyethyl)-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-6,9,18-t
ris[2-(sulfonatomethylamino)ethyl]-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]carbamoyl]-3-(sulfonatomet
hylamino)propyl]carbamoyl]propyl]carbamoyl]-3-(6-methyloctanoylamino)propyl]amino]methanesulfonate
216259 [[3-[[3-(1-hydroxyethyl)-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-6,9,18-tris[2-(sulfomethyl
amino)ethyl]-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]carbamoyl]-3-[[3-hydroxy-2-[[2-(6-methyloctanoyl
amino)-4-(sulfomethylamino)butanoyl]amino]butanoyl]amino]propyl]amino]methanesulfonic acid
5702027 pentasodium
[[3-[[1-[[1-[[12,15-dibutan-2-yl-3-(1-hydroxyethyl)-2,5,8,11,14,17,20-heptaoxo-6,9,18-tris[2-(sulfonatom
ethylamino)ethyl]-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]carbamoyl]-3-(sulfonatomethylamino)propyl]c
arbamoyl]-2-hydroxy-propyl]carbamoyl]-3-(6-methylheptanoylamino)propyl]amino]methanesulfonate

internal high similarity DBLink | Rows returned: 0

active | Cluster 1 | Additional Members: 50 | Rows returned: 132 3 Next >> 
LOPAC 00756 0
SPE01503692 0
LAT007G07 0
Prest1291 0
LAT007H07 0
LAT007E08 0

Service provided by the Mike Tyers Laboratory